This illustration provided by AstraZeneca depicts packaging for their medication Beyfortus. U.S. officials have approved a new long-acting drug to protect babies and toddlers against a respiratory virus that causes thousands of hospitalizations each year. The Food and Drug Administration on Monday, July 17, 2023 approved the injection for infants and children up to 2 years old. (AstraZeneca via AP)
By Matthew Perrone
U.S. officials on Monday approved the first long-acting drug to protect babies and toddlers against a respiratory virus that sends tens of thousands of American children to the hospital each year.
RSV is a cold-like nuisance for most healthy people, but it can be life-threatening in the very young and the elderly.
The Food and Drug Administration approved the injection for infants and children up to 2 years old who face increased risk of severe RSV.
“Today’s approval addresses the great need for products to help reduce the impact of RSV disease on children, families and the health care system” said FDA's Dr. John Farley in a statement.
Last year, a surge in RSV cases flooded U.S. hospitals with wheezing children. There are no vaccines for babies yet, though Pfizer and other companies are working on them.
AstraZeneca’s drug, to be sold under the brand name Beyfortus, is a laboratory-made version of an antibody that helps the immune system fight off RSV. Under the FDA approval, babies — including preterm infants — can receive a single injection to protect against their first season of RSV, which typically lasts about five months. Children up to age 2 can receive another dose to protect them during their second season facing the virus.
Beyfortus, which will be marketed in the U.S. by Sanofi, is already approved in Canada, Europe and the U.K. Sanofi did not immediately announce the U.S. price of the treatment.
FDA officials approved the drug based on three studies showing Beyfortus reduced the risk of RSV infection between 70% and 75% among infants and children 2 and younger.
Advisers to the Centers for Disease Control and Prevention will meet early next month to recommend exactly who should get the drug.
A similar antibody drug won FDA approval more than 20 years ago, but it’s only recommended for high-risk babies and requires monthly injections. Pediatricians say the drug is underutilized and they expect the longer-lasting effect of AstraZeneca's shot to improve uptake.
In the U.S., about 58,000 children younger than 5 are hospitalized for RSV each year and several hundred die.
After decades of setbacks for RSV research, drugmakers have made big strides this year, launching the first vaccines against the virus. In May, the FDA approved two RSV vaccines for older adults from GlaxoSmithKline and Pfizer. In August, the FDA is expected to make a decision on approving Pfizer’s vaccine for pregnant women, with the aim of passing along protection to their newborns.
The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institute’s Science and Educational Media Group. The AP is solely responsible for all content.
After the latest school shooting in Uvalde, Texas, it wouldn't be a surprise if the traumatic event takes a toll on your mental health — or that of your children. Amy Morin, the editor-in-chief of Verywell Mind and licensed psychotherapist, joined Cheddar News to share coping skills and offer advice about how to talk to your children about these increasingly common tragic events. “I think its important for parents to know what the school’s plan is, what the teacher's plan is, and then we can have our own plans with kids too," she noted. "It's so important for us to talk to kids about how they're feeling — guaranteed they've heard something about it, so ask them what they know already, use age-appropriate language, and rather than just dismissing their fears by saying don't worry about it or I'm sure you'll be safe, talk to them about their feelings."
An recently conducted AP-NORC poll found that majorities of the Black and Hispanic populations in the U.S. still find themselves either somewhat worried or extremely worried over the pandemic, while more than half of white Americans responded with either being not too worried or not worried at all. Dr. Chris Pernell, the chief strategic integration and health equity officer at University Hospital, joined Cheddar News to talk about how perceptions of COVID-19 differ between groups of Americans. "We’re still seeing people get infected, and because of the toll of the disproportionate impact, we have concerns among the Black and brown community about whether or not they have an increased risk of exposure because of where they work, because of the use of public transportation, because they live in homes that they may not be able to safely quarantine and or isolate in, and because they have at baseline chronic health conditions that may make coronavirus more severe in those persons," she said.
Judith Enck, a former regional administrator for the EPA and the president of Beyond Plastics, joined Cheddar News to talk about the role of plastics in the climate crisis and California's investigation of ExxonMobil and other oil companies for misleading the public on the ability to recycle plastics. "The reason why petrochemical companies like Exxon have gotten away with selling more and more plastic is that they've lied to the public and told us don't worry about all those negative upstream impacts and downstream impacts of plastics. Just be sure to recycle it. Well, guess what? Plastics largely are not recycled," Enck said.
Catching you up on what you need to know on April 29, 2022, with President Biden asking Congress for a $33 billion aid package for Ukraine, a shrinking GDP potentially leading to a recession, Beijing banning weddings and funerals while closings schools amid COVID, and more.
Virtual care and digital medicine provider Biofourmis recently raised $300 million in a Series D round led by General Atlantic and with participation from CVS Health. Biofourmis offers at-home care and digital therapies backed by artificial intelligence, which can remotely monitor patients while they are at home. The company says it hopes its technology can improve patient outcomes while reducing the cost and burden of care. Kuldeep Signh Rajput, Founder and CEO of Biofourmis, joins Cheddar News' Closing Bell to discuss.
Moderna is asking the FDA to consider emergency use authorization for its COVID vaccine to be used with children under 6 years old. Dr. Christina Johns, a senior medical advisor at PM Pediatrics, joined Cheddar News to talk about the pharmaceutical company's research into the safety and efficacy of the vaccine for the very youngest of children. "This is very exciting news because children met that goal in their neutralizing antibody response in this age group — means that we really can extrapolate a lot from what we know about data in adults," she said. "I will say that there's a caveat that we have not seen yet the full dataset released, so I'm waiting for that and my fingers are crossed for next week."
Mental health platform Real recently raised $37 million in a Series B round led by Owl Ventures. Through its mobile app, Real says it provides mental health care at a lower cost than traditional therapy and aims to make mental wellness a part of everyone's daily routine. The company also announced that U.S. soccer star Megan Rapinoe will serve as an adviser to the company. Ariela Safira, Founder & CEO of Real, joins Cheddar News' Closing Bell to discuss.
Catching you up on what you need to know on April 28, 2022, with Elon Musk mocking Twitter's top legal exec Vijaya Gadde on the platform itself, a probe in George Floyd's death finding discrimination within the Minneapolis police force, the latest California drought leading to new water restrictions, and more.
